NovaSeq 6000 Sequencing System is by far our most powerful instrument, designed to adapt to your needs.
Kits & Reagents
P1 reagents are now available for NextSeq 1000/NextSeq 2000 Systems, offering added flexibility to meet your project's needs
Selection & Planning Tools
A high-performing, fast, and integrated workflow for sensitive applications such as human whole-genome sequencing
Software & Informatics Products
DRAGEN v3.9 release now available with multi-cloud support, accuracy improvements and more
Fast, high-quality, sample-to-data services such as RNA and whole-genome sequencing
Optional primer pool now available with 99 amplicons and no human controls; kit volume sufficient for 384 samples
See what is possible through the latest advances in high-throughput sequencing technology
Connecting individuals, families, and communities to genomic solutions
All Investor Information
All Legal Information
Upgrade your MiSeqDx instrument from Windows 7 to Windows 10
All Support Tools
Product Support Services
Maximize identification of molecularly matched therapies with one biopsy, one test, one report
Cancer Research Products
Microbial Genomics Research
Microbial Genomics Products
Identifying variants could help select highly productive breeds that adapt to rapidly changing climates
The most comprehensive genotyping microarray on the market for pharmacogenomic research now at 25% off, restrictions apply
Complex Disease Research Products
When it comes to cancer, knowledge is power—and sequencing brought answers for one California couple
The collaboration will introduce VeriSeq NIPT Solution v2 in Southeast Asia
Reproductive Health Products
Illumina supports the release of a landmark consensus on whole-genome sequencing in the diagnosis of genetic diseases in newborns
Genetic Health Products
The MiSeqDx instrument is the first FDA-cleared in vitro diagnostic (IVD) next-generation sequencing (NGS) system.
MiSeqDx applications include FDA-cleared and FDA-approved assays for cystic fibrosis testing, colorectal cancer evaluation, and NGS-based assay development.
FDA-cleared next-generation sequencing panels for detection of causative and clinically relevant variants for cystic fibrosis.